Abstract
An anti-epileptic agent for use in the treatment of a neurological disorder other than epilepsy characterised in that the anti-epileptic agent is the sole active agent and that the daily dose of the anti-epileptic is less than 20% of the minimum daily dose which is effective for mood stabilisation or treatment of epileptic symptoms.
Claims
- An anti-epileptic agent for use in the treatment of a neurological disorder other than
- epilepsy characterised in that the anti-epileptic agent is the sole active agent and that the daily dose of the anti-epileptic is less than 20% of the minimum daily dose which is effective for mood stabilisation or treatment of epileptic symptoms.
- An anti-epileptic agent according to Claim 1, wherein the daily dose is less than 2.5% of the minimum daily dose of the anti-epileptic agent which is effective for mood stabilisation or treatment of epileptic symptoms.
- A pharmaceutical composition comprising a sub-therapeutic dose of an anti-epileptic agent as the sole active agent within the composition, together with a pharmaceutically acceptable carrier, diluent and/or excipient, wherein the sub-therapeutic dose is less than 20% of the minimum daily dose of the anti-epileptic agent which is effective for mood stabilisation or treatment of epileptic symptoms.
- A pharmaceutical composition according to Claim 3, wherein the composition is for use in the treatment of a neurological disorder other than epilepsy.
- A pharmaceutical composition according to Claim 3 or Claim 4, wherein the composition is adapted for transdermal administration.
- A pharmaceutical composition according to Claim 5, wherein the transdermal administration is via the oral mucosa and the composition is in the form of powders, a capsule, a tablet, a lozenge, a troche or a pastille.
- A pharmaceutical composition according to any of Claims 3 to 6, wherein the composition comprises a formulation which provides a controlled release or a sustained release of at least one active present in the composition.
- A method of treating a neurological disorder other than epilepsy in a subject in need thereof, including the step of administering to the subject an anti-epileptic agent as the sole active agent, wherein the daily dose of the anti-epileptic agent is less than 20% of the minimum daily dose which is effective for mood stabilisation or treatment of epileptic symptoms.
- An agent, composition or method according to any preceding claim, wherein the anti- epileptic agent is selected from brivaracetam, carbamazepine, clobazam, clonazepam, ethosuximide, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam,
- oxcarbazepine, phenobarbital, phenytoin, pregabalin, primidone, retigabine, rufinamide, safinamide, seletracetam, talampanel, tiagabine, topiramate, valproate, vigabatrin, zonisamide, benzodiazepines, barbiturates and sedative hypnotics.
- A combination of:
- (a) an anti-epileptic agent; and
- (b) an active selected from a stimulant, an anti-Parkinson's agent, an analgesic and an acetylcholinesterase inhibitor
- for use in the treatment of a neurological disorder other than epilepsy characterised in that the daily dose of the anti-epileptic agent is less than 2.5% of the minimum daily dose which is effective for mood stabilisation or treatment of epileptic symptoms.
- A pharmaceutical composition comprising:
- (a) A sub-therapeutic dose of an anti-epileptic agent;
- (b) an active selected from a stimulant, an anti Parkinson's agent, an analgesic and an acetylcholinesterase inhibitor; and
- (c) a pharmaceutically acceptable carrier, diluent and/or excipient,
- wherein the sub-therapeutic dose is less than 2.5% of the minimum daily dose which is effective for mood stabilisation or treatment of epileptic symptoms.
- A pharmaceutical composition according to Claim 11, wherein the composition is for use in the treatment of a neurological disorder other than epilepsy.
- A pharmaceutical composition according to Claim 11 or Claim 12, wherein the composition is adapted for transdermal administration.
- I l l
- A pharmaceutical composition according to Claim 13, wherein the composition is adapted for administration via the oral mucosa and is in the form of powders, a capsule, a tablet, a lozenge, a troche or a pastille.
- A pharmaceutical composition according to any of Claims 11 to 14, wherein the composition comprises a formulation which provides a controlled release or a sustained release of at least one active present in the composition.
- A method of treating a neurological disorder other than epilepsy in a subject in need thereof, including the step of administering to the subject a combination of (a) an anti-epileptic agent, and (b) an active selected from a stimulant, an anti-Parkinson's agent, an analgesic and an acetylcholinesterase inhibitor, wherein the daily dose of the anti-epileptic agent is less than 2.5% of the minimum daily dose which is effective for mood stabilisation or the treatment of epileptic symptoms.
- A combination, composition or method according to any of Claims 10 to 16, wherein the anti- epileptic agent is selected from brivaracetam, carbamazepine, clobazam, clonazepam, ethosuximide, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam,
- oxcarbazepine, phenobarbital, phenytoin, pregabalin, primidone, retigabine, rufinamide, safinamide, seletracetam, talampanel, tiagabine, topiramate, valproate, vigabatrin, zonisamide, benzodiazepines, barbiturates and sedative hypnotics.
- A combination, composition or method according to any of Claims 10 to 17, wherein the stimulant is selected from Adrafinil, Amantadine, Armodafinil, Carphedon, Modafinil, 4-
- Fluoroamphetamine, 4-Fluoromethamphetamine, 4-Methylmethcathinone, 4-MTA, a-PPP,
- Amphechloral, Amphetamine, Dextroamphetamine, Adderall, Amphetaminil,
- Benzphetamine, Bupropion, Cathinone, Chlorphentermine, Clobenzorex, Clortermine,
- Cypenamine, Diethylpropion, Dimethoxyamphetamine, Dimethylamphetamine,
- Dimethylcathinone, Diphenyl prolinol, Ephedrine, Epinephrine, Ethcathinone,
- Ethylamphetamine, Fencamfamine, Fenethylline, Fenfluramine, Fenproporex,
- Feprosidnine, Furfenorex, Levomethamphetamine, Lisdexamfetamine, L-lysine-d- amphetamine, MDMA, Mefenorex, Methamphetamine, Methcathinone,
- Methoxyphedrine, Methylone, Octopamine, Parahydroxyamphetamine, PMA, PMEA,
- PMMA, PPAP, Phendimetrazine, Phenmetrazine, Phentermine, Phenylephrine,
- Phenylpropanolamine, Prolintane, Propylamphetamine, Pseudoephedrine, Selegiline, Synephrine, Tenamphetamine, Xylopropamine; Piperazines, BZP, MeOPP, MBZP, mCPP, 2C-B-BZP, Tropanes, Brasofensine, CFT, Cocaethylene, Cocaine, Dimethocaine,
- Lometopane, PIT, PTT, TI-121, Tesofensine, Troparil, WF-23, WF-33, Cholinergics, Arecoline, Cotinine, Convulsants, Bicuculline, Gabazine, Pentetrazol, Picrotoxin,
- Strychnine, Thujone; Phenylaminooxazoles, 4-Methyl-aminorex, Aminorex, Clominorex, Fenozolone, Fluminorex, Pemoline, Thozalinone, Amineptine, Bemegride, BPAP,
- Clenbuterol, Clofenciclan, Cyclopentamine, Cyprodenate, Desoxypipradrol,
- Ethylphenidate, Ethamivan, Gilutensin, GYKI-52895, Hexacyclonate, Indanorex,
- Indatraline, Isometheptene, Mazindol, MDPV, Mesocarb, methylphenidate,
- Dexmethylphenidate, Naphthylisopropylamine, Nikethamide, Nocaine, Nomifensine, Phacetoperane, Phthalimidopropiophenone, Pipradrol, Prolintane, Propylhexedrine, Pyrovalerone, Tuamine, Vanoxerine, Yohimbine, Zylofuramine, Deanol,
- Diethylaminoethanol, Dimefline Hydrochloride, Etilamfetamine Hydrochloride, Fencamfamin Hydrochloride, Fenetylline Hydrochloride, Fenfluramine Hydrochloride, Fenproporex Hydrochloride, Lobeline Hydrochloride, Pentetrazol, and Propylhexedrine.
- A combination, composition or method according to any of Claims 10 to 18, wherein the anti- Parkinson's agent is selected from apomorphine, benserazide, benzatropine, bromocriptine, cabergoline, carbidopa, clozapine, domperidone, entacapone, levodopa, lisuride, orphenadrine, pergolide, piribedil, pramipexole, procyclidine, quetiapine, rasagiline, rivastigmine, ropinirole, rotigotine, selegiline, tolcapone, trihexyphenidyl, a dopamine agonist, a dopamine decarboxylase inhibitor, a catechol O methyl transferase (COMT) enzyme inhibitor, a monoamine oxidase-B inhibitor and an N-methyl-D-aspartate blocker.
- A composition, composition or method according to any of Claims 10 to 19, wherein
- acetylcholinesterase inhibitor is selected from tacrine, donepezil, galantamine and rivastigmine.
Applicants
-
Gosforth Ct Holdings Pty Ltd
Explore more patents:
-
Bird Philip
Explore more patents:
Inventors
CPC Classifications
-
A61K2300/00
Explore more patents:
-
A61K31/197
Explore more patents:
-
A61K31/20
Explore more patents:
-
A61K31/4166
Explore more patents:
-
A61K31/4192
Explore more patents:
-
A61K31/445
Explore more patents:
-
A61K31/55
Explore more patents:
-
A61K31/7048
Explore more patents:
-
A61K45/06
Explore more patents:
IPC Classifications
-
A61K31/197
Explore more patents:
-
A61K31/20
Explore more patents:
-
A61K31/4166
Explore more patents:
-
A61K31/4192
Explore more patents:
-
A61K31/55
Explore more patents:
-
A61K31/7048
Explore more patents:
-
A61K45/06
Explore more patents:
-
A61K9/00
Explore more patents:
-
A61P25/00
Explore more patents:
-
A61P25/16
Explore more patents:
-
A61P25/18
Explore more patents:
-
A61P25/28
Explore more patents:
Download PDF
Document Preview
Document History
- Publication: Jan 17, 2013
-
Application:
Jul 9, 2012
EP 2012063419 W
-
Priority:
Jul 8, 2011
GB 201111712 A